Plaque-Stabilizing Effect of Angiotensin-Converting Enzyme Inhibitor and/or Angiotensin Receptor Blocker in a Rabbit Plaque Model

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 3, 2013, Pages 257-266

  Hotchi, Junko ^a   Hoshiga, Masaaki ^a   Takeda, Yoshihiro ^a   Yuki, Takahito ^a   Fujisaka, Tomohiro ^a   Ishihara, Tadashi ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Plaque stabilization

Indexed keywords

5 ACETYL 4,5,6,7 TETRAHYDRO 2 PROPYL 3 [2' (1H TETRAZOL 5 YL) 4 BIPHENYLYLMETHYL]IMIDAZO[4,5 C]PYRIDINE 4 CARBOXYLIC ACID 1 ETHYLPROPOXYCARBONYLOXYMETHYL ESTER; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATIN; GELATINASE B; IMIDAPRIL; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD PRESSURE; CHOLESTEROL DIET; CONTROLLED STUDY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTIMA; MACROPHAGE; MALE; NONHUMAN; RABBIT; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; IMMUNOHISTOCHEMISTRY; LIPIDS; MALE; PLAQUE, ATHEROSCLEROTIC; RABBITS;

EID: 84875390740     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14266     Document Type: Article

References (45)

1. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W: The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation, 2006; 114: 2850-2870
2. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W: The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation, 2006; 114: 2871-2891
3. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003; 362: 782-788
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342: 145-153
5. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003; 362: 772-776
6. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation, 2006; 114: 838-854
7. Tsuyuki RT, McDonald MA: Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation, 2006; 114: 855-860
8. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S: Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens, 2007; 25: 951-958
9. Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M, Tanouchi J, Yamada Y, Kamada T: Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation, 2001; 103: 630-633
10. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation, 2000; 101: 1372-1378
11. Hernández-Presa MA, Bustos C, Ortego M, Tuñón J, Ortega L, Egido J: ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol, 1998; 153: 1825-1837
12. Johnstone MT, Perez AS, Nasser I, Stewart R, Vaidya A, Al Ammary F, Schmidt B, Horowitz G, Dolgoff J, Hamilton J, Quist WC: Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation, 2004; 110: 2060-2065
13. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T: Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Hypertens Res, 2008; 31: 1199-1208
14. Grothusen C, Bley S, Selle T, Luchtefeld M, Grote K, Tietge UJ, Drexler H, Schieffer B: Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis, 2005; 182: 57-69
15. Blessing E, Preusch M, Kranzhöfer R, Kinscherf R, Marx N, Rosenfeld ME, Isermann B, Weber CM, Kreuzer J, Gräfe J, Katus HA, Bea F: Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis, 2008; 199: 295-303
16. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH: Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest, 1993; 91: 1453-1458
17. Imanishi T, Kuroi A, Ikejima H, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T: Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Hypertens Res, 2008; 31: 575-584
18. Fukuda D, Enomoto S, Nagai R, Sata M: Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother, 2009; 63: 754-761
19. Okabe T, Hoshiga M, Negoro N, Nakakoji T, Arishiro K, Ishihara T, Ueno H, Hanafusa T: Rabbit plaque models closely resembling lesions in human coronary artery disease. Int J Cardiol, 2011; 147: 271-277
20. Hashimoto Y, Harada Y, Narita H, Naito K, Murata S: The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist. J Cardiovasc Pharmacol, 1997; 29: 284-290
21. Hashimoto Y, Ohashi R, Kurosawa Y, Minami K, Kaji H, Hayashida K, Narita H, Murata S: Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. J Cardiovasc Pharmacol, 1998; 31: 568-575
22. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T: Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol, 2007; 49: 1482-1489
23. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation, 1998; 97: 2433-2444
24. Nakashima Y, Wight TN, Sueishi K: Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res, 2008; 79: 14-23
25. Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, von Eckardstein A, Exley A, Goddard M, Hofker M, Hurt-Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W, Pentikäinen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B, de Winther M; MAFAPS Consortium: Rupture of the atherosclerotic plaque: does a good animal model exist ? Arterioscler Thromb Vasc Biol, 2003; 23: 535-542
26. Napoli C, Palinski W: Unraveling the mechanisms of plaque rupture in murine models. Circulation, 2002; 106: e186
27. Shiomi M, Ito T, Tsukada T, Yata T, Ueda M: Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study. Arterioscler Thromb, 1994; 14: 931-937
28. Tanaka E, Shimokawa H, Kamiuneten H, Eto Y, Matsumoto Y, Morishige K, Koike G, Yoshinaga M, Egashira K, Tokunaga O, Shiomi M, Takeshita A: Disparity of MCP-1 mRNA and protein expressions between the carotid artery and the aorta in WHHL rabbits: one aspect involved in the regional difference in atherosclerosis. Arterioscler Thromb Vasc Biol, 2003; 23: 244-250
29. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995; 92: 1355-1374
30. Libby P: Molecular bases of the acute coronary syndromes. Circulation, 1995; 91: 2844-2850
31. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol, 2007; 292: C82-97
32. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol, 2001; 2: 108-115
33. Mukaida N, Harada A, Matsushima K: Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/ MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev, 1998; 9: 9-23
34. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, Mehta JL: Increased angiotensin II type 1 recep tor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol, 1998; 18: 1433-1439
35. Ypsilantis P, Didilis VN, Politou M, Bougioukas I, Bougioukas G, Simopoulos C: A comparative study of invasive and oscillometric methods of arterial blood pressure measurement in the anesthetized rabbit. Res Vet Sci, 2005; 78: 269-275
36. Kuzuya M, Iguchi A: Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb, 2003; 10: 275-282
37. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation, 1998; 97: 2433-2444
38. Takai S, Yamamoto D, Jin D, Inagaki S, Yoshikawa K, Tanaka K, Miyazaki M: Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur J Pharmacol, 2007; 568: 231-233
39. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M: Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol, 2007; 43: 670-676
40. Kojima C, Ino J, Ishii H, Nitta K, Yoshida M: MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation. J Atheroscler Thromb, 2010; 17: 97-105
41. Hansson GK, Holm J, Jonasson L: Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol, 1989; 135: 169-175
42. Hansson GK, Libby P, Schonbeck U, Yan ZQ: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res, 2002; 91: 281-291
43. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R: Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol, 2007; 18: 1093-1102
44. Silva-Filho JL, Souza MC, Henriques MG, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA: AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol, 2011; 48: 1835-1843
45. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559